Boy or girl? Mother's BP may predict sex of baby

January 13, 2017

Toronto, Jan 13: The sex of a baby may be predicted by the mother's blood pressure, according to a new study which found that women with lower BP before pregnancy are more likely to give birth to a girl.

babyResearchers led by Dr Ravi Retnakaran, endocrinologist at Mount Sinai Hospital in Canada found that while higher blood pressure was an indication that a boy was more likely to be conceived, women with lower blood pressure tended to give birth to a girl.

This "suggests that a woman's blood pressure before pregnancy is a previously unrecognised factor that is associated with her likelihood of delivering a boy or a girl," said Retnakaran.

"This novel insight may hold implications for both reproductive planning and our understanding of the fundamental mechanisms underlying the sex ratio in humans," he said.

The possibility of predicting the sex of the baby in early pregnancy has long been a topic of public fascination, spawning numerous theories of maternal characteristics associated with the presence of a male or female foetus.

These observations raise the possibility that there may be underlying differences that relate to a woman's likelihood of sex-specific fetal loss and hence her likelihood of delivering a boy or girl. However, little is known about such factors in humans.

Researchers established a unique pre-conception cohort consisting of young women who were planning to have a pregnancy in the near future and used the model to evaluate the relationship between maternal pre-pregnancy health and the sex of the baby.

Participants underwent baseline medical assessment at recruitment and then, whenever they subsequently became pregnant, were followed across the pregnancy up to delivery through their clinical care.

Beginning in February 2009, researchers recruited 3375 women in Liuyang, China. Of these, 1,692 women were assessed for blood pressure, cholesterol, triglycerides, and glucose.

After the exclusion of 281 women who were potentially pregnant at their baseline assessment based on back-dating of the length of gestation at delivery, the study population for the analysis consisted of 1,411 women who were assessed at median 26.3 weeks before pregnancy.

Their pregnancies resulted in the delivery of 739 boys and 672 girls.

After adjustment for age, education, smoking, BMI, waist, LDL cholesterol, HDL cholesterol, triglycerides and glucose, mean adjusted systolic blood pressure before pregnancy was found to be higher in women who subsequently had a boy than in those who delivered a girl (106.0 vs 103.3 millimetres of mercury).

Higher maternal blood pressure before pregnancy emerged as an independent predictor of subsequently delivering a boy.

The research was published in the American Journal of Hypertension.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
May 26,2020

Tedros Adhanom Ghebreyesus, the World Health Organisation's (WHO) Director-General, said that a clinical trial of hydroxychloroquine (HCQ) on COVID-19 patients has come to "a temporary pause", while the safety data of the the anti-malaria drug was being reviewed.

According to the WHO chief, The Lancet medical journal on May 22 had published an observational study on HCQ and chloroquine and its effects on COVID-19 patients that have been hospitalized, reports Xinhua news agency.

The authors of the study reported that among patients receiving the drug, when used alone or with a macrolide, they estimated a higher mortality rate.

"The Executive Group of the Solidarity Trial, representing 10 of the participating countries, met on Saturday (May 23) and has agreed to review a comprehensive analysis and critical appraisal of all evidence available globally," Tedros said in a virtual press conference on Monday.

The review will consider data collected so far in the Solidarity Trial and in particular robust randomized available data, to adequately evaluate the potential benefits and harms from this drug, he said.

"The Executive Group has implemented a temporary pause of the HCQ arm within the Solidarity Trial while the safety data is reviewed by the Data Safety Monitoring Board. The other arms of the trial are continuing," Tedros added.

WHO initiated the Solidarity Trial, a plan to evaluate the safety and efficacy of four drugs and drug combinations against COVID-19 more than two months ago, which include HCQ.

According to the WHO, over 400 hospitals in 35 countries are actively recruiting patients and nearly 3,500 patients have been enrolled from 17 countries under the Solidarity Trial.

Tedros added that the safety concern over the drug related only to the use of HCQ and chloroquine in COVID-19, and "these drugs are accepted as generally safe for use in patients with autoimmune diseases or malaria".

"WHO will provide further updates as we know more," he added.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
January 5,2020

Washington D.C., Jan 5: After a woman filed a lawsuit against a diet soda company, the California court has declared that the beverage does not promise to help buyers in losing weight.

The woman had gulped down the drink for over a decade but did not lose inches as a result.

The three-judge panel declared during the hearing: "The prevalent understanding of the term in (the marketplace) is that the 'diet' version of a soft drink has fewer calories than its 'regular' counterpart."

However, the members of the US 9th circuit court have felt that the consumers tend to make out something of their own that is unreasonable and eventually hamper the reputation of brands through a deceptive allegation, reports Fox News.

The response was due to a misleading case filed against Diet Dr Pepper by Shana Becerra from Santa Rosa, California. Shana claimed that she has been addictively purchasing the low-calorie beverage for the past 13 years hoping for losing some fat but failed to lose even a single inch.

The woman also stated that the attractive and fit models misled her into believing that drink will help her in perfecting her body like them.

However, the court's decision was that advertisements are for representational purposes only. "Cannot be reasonably understood to convey any specific meaning at all," as written by Judge Jay Bybee.

Shana had last week made such allegation against Diet coke as well where the court came to a similar verdict. She claimed that she had found various studies where it is evident that the artificial sweetener aspartame used in diet beverages actually boosts weight gain.

But the artificial sweetener is approved in by the concerned administrative department and thus is used in most American drinks.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
April 14,2020

There is no evidence that the Bacille Calmette-Guerin (BCG) vaccine, which is primarily used against tuberculosis, protects people against infection with the novel coronavirus, the World Health Organization (WHO) said.

The WHO therefore didn't recommend BCG vaccination for the prevention of COVID-19 in the absence of evidence, according to its daily situation report on Monday, Xinhua news agency reported.

"There is experimental evidence from both animal and human studies that the BCG vaccine has non-specific effects on the immune system. These effects have not been well characterized and their clinical relevance remains unknown," WHO stated.

Two clinical trials addressing the question are underway, and WHO will evaluate the evidence when it is available, it noted.

BCG vaccination prevents severe forms of tuberculosis in children and diversion of local supplies may result in an increase of disease and deaths from the tuberculosis, it warned.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.